According to the NHRA's website, its mission is "to regulate the provision of healthcare in Bahrain and ensure appropriateness, continuity, efficiency and safety in delivering health services, both in the governmental and private sector.

[3] The CEO Dr Mariam Al Jalahma mentioned in her interview to the Oxford Business Group that NHRA ensures that there are no malpractices in the import of medical equipment and essential drugs.

It is also ready to receive reports about medical and professional errors and serious accidents by institutions in order to ensure action is taken, to improve performance and to take disciplinary measures against health guilty professions practitioners".

[5] In December 2020, NHRA announced it has officially approved the registration of Sinopharm’s COVID-19 vaccine after the submission of all related documentation by G42 Healthcare, the company's exclusive distributor in the Middle East and North Africa.

[8] On 25 January 2021, the National Health Regulatory Authority (NHRA) announced that it approved the emergency use of the Oxford–AstraZeneca COVID-19 vaccine manufactured by the Serum Institute of India under the name ‘Covishield’.